Middle East and Africa Migraine Treatment Market – Industry Trends and Forecast to 2027

Healthcare
Published Report
Jun 2020
MEA
350 Pages
No of Tables: 254
No of Figures: 49

Middle East & Africa Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies, Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, Others), Product Type (Prescription, Over the Counter), Type (Branded, Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Market Analysis and Insights: Middle East and Africa Migraine Treatment Market

Migraine treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with the CAGR of 8.1% in the forecast period of 2020 to 2027 and expected to reach USD 106.16 million by 2027. Growing female population and availability of large number of generic drugs are the major drivers which propelled the demand of the market in the forecast period.

Migraine treatment comprises features such as introduction of novel therapies for the treatment of acute migraine will impact in launching new product by the manufactures into the market which enhance its demand as well as increasing prevalence of migraine has enhanced the demand of migraine treatment. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop innovative and advanced migraine treatment drugs which expected to provide various other opportunities in the migraine treatment market. However, adverse effects of drugs expected to restraint the market growth in the forecast period.

The migraine treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Migraine treatment Market Scope and Market Size

Migraine treatment market is segmented on the basis of types of migraine, treatment, product type, type, route of administration, end-user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of types of migraine, the market is segmented into episodic, chronic, migraine with aura and others. In 2020, episodic segment is expected to dominate the market as it is the most prevalent form of migraine characterized by 0 to 14 headaches days per month, as well as higher cases of migraine attacks increased the demand of episodic migraine treatment as compared to other types of migraine.

On the basis of treatment, the market is segmented into acute/abortive treatment, preventive/prophylactic treatment, non-pharmacological therapies and devices. In 2020, acute/abortive treatment is expected to dominate the market as most of the pharmaceutical companies and patients alike have historically focused on acute treatment of migraines as compared to preventive treatments.

On the basis of route of administration, the market is segmented into oral, parenteral, nasal sprays and others. In 2020, oral segment is expected to dominate the market due to the presence of large number of oral medications for migraine treatment.

On the basis of product type, the market is segmented into prescription and over the counter. In 2020, prescription segment is expected to dominate the market as prescription drugs hold the highest market share including ergotamines, beta blockers among others are available on prescription basis.

On the basis of type, the market is segmented into branded and generic. In 2020, generic segment is expected to dominate the market as migraine treatment market is a well-established market and majority of the branded drugs lose their validity after a time interval. Another factor responsible for the dominance of generic segment is low cost of drugs.

On the basis of end user, the market is segmented into hospitals, clinics, homecare and others. In 2020, hospital segment is expected to dominate the market as most of the patients who doesn’t received proper treatment for acute migraine, their migraine attacks turn into an episodic one and a chronic one and the proper treatment for chronic migraine is available at hospitals.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2020, hospital pharmacies segment is expected to dominate the market as most of the prescription drugs are available only at hospital pharmacies.

Migraine treatment Market Country Level Analysis

The migraine treatment market is analysed and market size information is provided by type of migraine, treatment, route of administration, product type, type, end user and distribution channel.

The countries covered in migraine treatment market report are the South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of Middle East and Africa in the Middle East and Africa.

South Africa is dominating the Middle East and Africa migraine treatment market a significant number of companies operating in this market have considered the country as an important manufacturing hub as it offers several benefits. This makes the country not only an important consumer but also a manufacturing choice.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as sales, launch of new drugs, country demographics, and regulatory acts are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Technological Advancement for The Treatment of Acute Migraine is Propelling the Market Growth

Migraine treatment market also provides you with detailed market analysis for every country growth in migraine treatment industry with migraine treatment sales, impact of advancement in the migraine treatment and changes in regulatory scenarios with their support for the migraine treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Migraine treatment Market Share Analysis

Migraine treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to migraine treatment market.

The major players covered in the report are Amgen Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, Allergan, Abbott, AstraZeneca, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd, Lundbeck, Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc.), Pfizer Inc., Sun Pharmaceutical Industries Ltd among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch, approval, partnership and agreement are also initiated by the companies’ worldwide which are also accelerating the migraine treatment market.

For instance,

In May 2017, Teva signed an agreement with Otsuka Pharmaceutical Co., Ltd. to develop and commercialize Teva’s drug (TEV -48125), an anti- calcitonin gene-related peptide monoclonal antibody for the prevention of migraine. As prevalence of migraine is too high in Japan this agreement has benefitted both the company by providing increased product sales which led to high revenue collection.

In June 2011, Sun Pharmaceutical Industries Ltd. has received U.S. FDA approval for sumatriptan succinate injections used in the treatment of acute migraine attacks. This approval has strengthened the company’s product portfolio in the market.

Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the migraine treatment market which also provides the benefit for organisation to improve their offering for migraine treatment.

Customization Available: Middle East and Africa Migraine Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-54075

LIST OF TABLES

TABLE 1 GENERIC DRUGS FOR MIGRAINE TREATMENT

TABLE 2 PIPELINE DRUGS FOR MIGRAINE TREATMENT

TABLE 3 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY PIPELINE ANALYSIS

TABLE 4 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA EPISODIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA MIGRAINE WITH AURA IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA CHRONIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TRAETMENT, 2018-2027 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TRATMENT, 2018-2027 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ORAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA PARENTERAL IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA NASAL SPRAYS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA PRESCRIPTION IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA OVER THE COUNTER IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA GENERIC IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA BRANDED IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA HOSPITALS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA CLINICS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA HOMECARE IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 MIDDLE EAST & AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 MIDDLE EAST & AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 MIDDLE EAST & AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 MIDDLE EAST & AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 78 MIDDLE EAST & AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 79 MIDDLE EAST & AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 81 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 82 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 83 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 84 MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 85 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 86 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 SAUDI ARABIA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 SAUDI ARABIA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 SAUDI ARABIA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 90 SAUDI ARABIA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 SAUDI ARABIA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 SAUDI ARABIA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 SAUDI ARABIA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 SAUDI ARABIA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 SAUDI ARABIA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 SAUDI ARABIA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 SAUDI ARABIA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 99 SAUDI ARABIA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 100 SAUDI ARABIA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 SAUDI ARABIA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 SAUDI ARABIA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 103 SAUDI ARABIA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 104 SAUDI ARABIA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 105 SAUDI ARABIA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 106 SAUDI ARABIA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 SAUDI ARABIA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 110 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 112 SAUDI ARABIA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 113 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 114 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 SOUTH AFRICA ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 SOUTH AFRICA NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 SOUTH AFRICA TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 118 SOUTH AFRICA OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 SOUTH AFRICA ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 121 SOUTH AFRICA ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 122 SOUTH AFRICA ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 SOUTH AFRICA OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 SOUTH AFRICA PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 125 SOUTH AFRICA ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 126 SOUTH AFRICA CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 127 SOUTH AFRICA SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 128 SOUTH AFRICA ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 SOUTH AFRICA NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 SOUTH AFRICA BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 SOUTH AFRICA BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 SOUTH AFRICA CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLIONX`)

TABLE 133 SOUTH AFRICA ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 SOUTH AFRICA NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 SOUTH AFRICA DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 137 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 138 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 139 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 140 SOUTH AFRICA MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 141 UAE MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 142 UAE MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 143 UAE ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 144 UAE NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 UAE TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 146 UAE OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 147 UAENONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 148 UAE ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 149 UAE ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 150 UAE ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 UAE OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 UAE PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 UAE ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 UAE CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 UAE SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 UAE ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 UAE NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 UAE BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 UAE BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 UAE CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 UAE ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 UAE NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 UAE DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 UAE MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 UAE MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 166 UAE MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 167 UAE MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 168 UAE MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 169 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 170 ISRAEL MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 171 ISRAEL ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 172 ISRAEL NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 173 ISRAEL TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 174 ISRAEL OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 ISRAELNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 ISRAEL ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 ISRAEL ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 ISRAEL ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 ISRAEL OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 ISRAEL PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 ISRAEL ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 ISRAEL CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 ISRAEL SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 ISRAEL ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 ISRAEL NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 ISRAEL BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 187 ISRAEL BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 188 ISRAEL CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 189 ISRAEL ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 190 ISRAEL NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 191 ISRAEL DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 192 ISRAEL MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 193 ISRAEL MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 194 ISRAEL MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 195 ISRAEL MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 196 ISRAEL MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 197 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 198 KUWAIT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 199 KUWAIT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 200 KUWAIT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 201 KUWAIT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 202 KUWAIT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 203 KUWAITNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 204 KUWAIT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 205 KUWAIT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 206 KUWAIT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 207 KUWAIT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 208 KUWAIT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 209 KUWAIT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 210 KUWAIT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 211 KUWAIT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 212 KUWAIT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 213 KUWAIT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 214 KUWAIT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 215 KUWAIT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 216 KUWAIT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 217 KUWAIT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 218 KUWAIT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 219 KUWAIT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 220 KUWAIT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 221 KUWAIT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 222 KUWAIT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 223 KUWAIT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 224 KUWAIT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 225 EGYPT MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 226 EGYPT MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 227 EGYPT ACUTE/ABORTIVE TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 228 EGYPT NONSPECIFIC THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 229 EGYPT TRIPTANS IN MIGRAINE TREATMENT MARKET, BY TREATMENT , 2018-2027 (USD MILLION)

TABLE 230 EGYPT OPIATES/OPOIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 231 EGYPTNONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 232 EGYPT ERGOT ALKALOID IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 233 EGYPT ANTI-NAUSEA IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 234 EGYPT ADJUNCTIVE THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 235 EGYPT OTHERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 236 EGYPT PREVENTIVE/PROPHYLACTIC TREATMENT IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 237 EGYPT ANTICONVULSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 238 EGYPT CALCITONIN GENE-RELATED PEPTIDE THERAPY IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 239 EGYPT SELECTIVE SEROTONIN RECEPTOR AGONISTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 240 EGYPT ANTIDEPRESSANTS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 241 EGYPT NSAIDS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 242 EGYPT BLOOD PRESSURE-LOWERING MEDICATIONS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 243 EGYPT BETA BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 244 EGYPT CALCIUM-CHANNEL BLOCKERS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 245 EGYPT ANGIOTENSIN BLOCKERS: ACE-IS/ARBS IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 246 EGYPT NON-PHARMACOLOGICAL THERAPIES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 247 EGYPT DEVICES IN MIGRAINE TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 248 EGYPT MIGRAINE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 249 EGYPT MIGRAINE TREATMENT MARKET, BY PRODUCT TYPE, 2018-2027 (USD MILLION)

TABLE 250 EGYPT MIGRAINE TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 251 EGYPT MIGRAINE TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 252 EGYPT MIGRAINE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 253 REST OF MIDDLE EAST & AFRICA MIGRAINE TREATMENT MARKET, BY TYPES OF MIGRAINE, 2018-2027 (USD MILLION)

TABLE 254 SUBSIDIARIES OF JANSSEN MIDDLE EAST AND AFRICA SERVICES, LLC

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE

Enterprise User 4200.00
Single User 3500.00
DBMR Factbook 2000.00
DBMR Prime 5500.00
DBMR Supreme 7500.00

Buy Now Add to Cart

Advance Formative Research Customization

Request for bulk
Reports

Why Choose Us

Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Frequently Asked Questions

Browse Related Reports

Global Migraine Treatment Market – Industry Trends and Forecast to 2029

Asia-Pacific Migraine Treatment Market – Industry Trends and Forecast to 2029

Europe Migraine Treatment Market – Industry Trends and Forecast to 2027

North America Migraine Treatment Market – Industry Trends and Forecast to 2027

Browse Related Blogs

Global Migraine Treatment Market is Expected to Grow at CAGR of 12.4% in the Forecast Period of 2020 to 2027

Global Migraine Treatment Market is Expected to Reach an Estimated Valuation of USD 12,943.53 Million by 2027

Browse Related Infographics

Global Migraine Treatment Market is Expected to Register a Healthy CAGR in the Forecast Period of 2019 to 2027